Advertisement

Advances in Targeted Cancer Therapy

  • Paul L. Herrling
  • Alex Matter
  • Richard M. Schultz

Part of the Progress in Drug Research book series (PDR, volume 63)

Table of contents

  1. Front Matter
    Pages i-vii
  2. Henk M. W. Verheul, Herbert M. Pinedo
    Pages 67-91
  3. Fortunato Ciardiello, Ferdinando De Vita
    Pages 93-115
  4. Carlo Palmieri, R. Charles Coombes, David M. Vigushin
    Pages 147-191
  5. Elizabeth Rayburn, Wei Wang, Ruiwen Zhang, Hui Wang
    Pages 227-274
  6. Back Matter
    Pages 301-303

About this book

Introduction

There have been tremendous advances in our understanding of molecular and tumor biology during the past few years. In the field of cancer therapeutics, it is expected that cytotoxic drug approaches will be gradually replaced with treatments based on biological targeted approaches. Hopefully these new targeted therapies will significantly increase efficacy and lack the devastating and troublesome side effects elicited by cytotoxic chemotherapy.

This volume is the first book to cover the general topic of targeted cancer therapy. It presents a range of targets such as tumor angiogenesis, cell cycle control and cell signalling, COX-2, apoptosis/cell survival, invasion and metastasis and approaches like kinase inhibitors, antisense, and antibody-based therapeutics. The emphasis is on preclinical development, including target validation, development of biomarkers, strategies for combination approaches, and development of resistance. The particular challenges involved in translating these data to clinical application are discussed.
This volume should be of broad general interest to researchers and clinicians involved in cancer therapy as well as other scientists interested in current strategies for cancer treatment.

Keywords

angiogenesis antibody apoptosis cancer cancer prevention cancer therapy cancer treatment cell metastasis pharmacology prevention receptor tumor

Editors and affiliations

  • Paul L. Herrling
    • 1
  • Alex Matter
    • 2
  • Richard M. Schultz
    • 3
  1. 1.Novartis International AGBaselSwitzerland
  2. 2.Novartis Institute for Tropical DiseasesSingaporeSingapore
  3. 3.IndianapolisUSA

Bibliographic information